Oppenheimer Downgrades Cartesian Therapeutics to Peer Perform
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has downgraded Cartesian Therapeutics (NASDAQ:RNAC) from Outperform to Peer Perform.
July 02, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Oppenheimer analyst Matthew Biegler has downgraded Cartesian Therapeutics from Outperform to Peer Perform, indicating a less favorable outlook for the stock.
The downgrade from a reputable analyst can negatively impact investor sentiment and lead to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100